// App-Quantinova.ai

2828 : Cytoreduction Plus Low-Dose Aspirin Versus Cytoreduction in Monotherapy As Primary Prophylaxis of Thrombosis in Patients with Essential Thrombocythemia.

Researchers

Presenter

  • Arturo Pereira

Principal Investigators

  • Hemostasis

  • Eduardo Arellano-Rodrigo

  • Juan Carlos Hernandez-Boluda

  • Francisco Cervantes

  • Carlos Besses

Medical Centers

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Hematology Division, Hospital Clinico, Valencia, Spain

  • Hospital Clinic, IDIBAPS, Barcelona, Spain

  • Hemotherapy & Hematology, Hospital del Mar, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Essential thrombocythemia

  • Extreme thrombocytosis

  • Venous thrombosis

Biomarkers

  • Lymphocyte count

  • White Blood Cell

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

  • Anagrelide hydrochloride

  • Interferon

  • Busulfan

  • Aspirin

  • Albyl-E

  • Mofezolac

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved